Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751715 | 1.00 | GPR119 (0.50) | GPR119TACR1USP30JAK2JAK1 | |
| SCHEMBL3806425 | 1.00 | GPR119 (0.50) | GPR119TACR1USP30JAK2JAK1 | |
| SCHEMBL952059 | 1.00 | GPR119 (0.50) | GPR119TACR1USP30JAK2JAK1 | |
| SCHEMBL14404380 | 1.00 | GPR119 (0.50) | GPR119TACR1USP30JAK2JAK1 | |
| SCHEMBL5005899 | 0.91 | GPR119 (0.50) | GPR119TACR1USP30JAK2JAK1 | |
| SCHEMBL5010481 | 0.91 | GPR119 (0.50) | GPR119TACR1USP30JAK2JAK1 | |
| SCHEMBL5005902 | 0.91 | GPR119 (0.50) | GPR119TACR1USP30JAK2JAK1 | |
| SCHEMBL5006446 | 0.91 | GPR119 (0.50) | GPR119TACR1USP30JAK2JAK1 | |
| SCHEMBL23982326 | 0.88 | TACR1 (0.49) | GPR119TACR1USP30JAK2JAK1 | |
| SCHEMBL3702527 | 0.88 | PDE4B (0.52) | GPR119TACR1USP30JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580821-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580821-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580821-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2188266-B1 | Novel piperazine amide derivatives | HOFFMANN LA ROCHE (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-8288541-B2 | Piperazine amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2004605-B1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-20110105561-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | GRUNDSCHOBER CHRISTOPHE | 2011-05-05 | — | — | US | disclosed |
| US-20110105561-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | GRUNDSCHOBER CHRISTOPHE | 2011-05-05 | — | — | US | disclosed |
| US-20110105561-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | GRUNDSCHOBER CHRISTOPHE | 2011-05-05 | — | — | US | disclosed |
| US-7872022-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872022-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872022-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2188266-A2 | NOVEL PIPERAZINE AMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009021868-A2 | NOVEL PIPERAZINE AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048264-A1 | PIPERAZINE AMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | HOFFMAN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | HOFFMAN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | HOFFMAN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048264-A1 | PIPERAZINE AMIDE DERIVATIVES | NR1H2, NR1H3, NR1I2 | GPR119 38/4885TACR1 379/4885USP30 2721/4885 |
| US-20110105561-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | SLC6A4, SLC6A1, SLC1A2 | GPR119 328/4885TACR1 71/4885USP30 4090/4885 |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A1, SLC1A2 | GPR119 328/4885TACR1 71/4885USP30 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.